Reyvow in 2026: It's Not a Shortage — It's a Discontinuation

If you've been searching for information about a Reyvow shortage, here's what you need to know upfront: Reyvow (Lasmiditan) is not just in shortage — it's being permanently discontinued by Eli Lilly.

This means that unlike a typical drug shortage where supply eventually recovers, Reyvow will not be coming back. In this article, we'll cover the current status, what led to this point, how much Reyvow costs while it's still available, and what your options are going forward.

Is Reyvow Still in Shortage?

The FDA's Drug Shortages database listed Reyvow with a status of "to be discontinued" in November 2025. Eli Lilly confirmed the decision shortly after.

Here are the key facts:

• Both the 50 mg and 100 mg tablets are affected
• U.S. distribution is scheduled to end on May 31, 2026
• Remaining pharmacy inventory may be available through approximately June 2026, depending on location
• The decision was a voluntary business decision by Eli Lilly — not related to safety, efficacy, or quality
• No generic version of Lasmiditan exists or is expected

So while you may still find Reyvow at some pharmacies today, it's not a matter of waiting for the supply to bounce back. Every tablet currently in the supply chain is part of the final batch.

Why Is Reyvow Being Discontinued?

Eli Lilly has described the discontinuation as a business decision. While they haven't disclosed detailed financial reasons, the migraine treatment market shifted significantly since Reyvow launched in 2020:

• CGRP-targeting medications (gepants) like Ubrelvy, Nurtec ODT, and Zavzpret have become the preferred newer-generation acute migraine treatments
• Reyvow's Schedule V controlled substance status added prescribing complexity
• The mandatory 8-hour driving restriction after each dose made it impractical for many patients
• Drowsiness and dizziness were common side effects that limited daily usability

For a more detailed explanation, see our article on why Reyvow is so hard to find.

How Much Does Reyvow Cost in 2026?

While supply lasts, Reyvow pricing remains similar to previous years:

• Cash price (no insurance): approximately $850–$1,100 for 8 tablets
• With the Reyvow Savings Card: commercially insured patients may pay as little as $0 per fill (up to $3,400 in savings per calendar year)
• With discount cards (SingleCare, GoodRx): approximately $689–$800 for 8 tablets

The Reyvow Savings Card from Eli Lilly is still active as of early 2026, but it's only available to patients with commercial insurance — not Medicare, Medicaid, VA, or TRICARE. It may be phased out as the drug exits the market.

The Lilly Cares Foundation patient assistance program has also included Reyvow for eligible uninsured patients. Check our guide on saving money on Reyvow for full details.

What Are Your Options Now?

With Reyvow going away, here are the acute migraine treatments you should discuss with your doctor:

Gepants (CGRP Receptor Antagonists)

• Ubrelvy (Ubrogepant): Oral tablet, 50 mg or 100 mg. Not a controlled substance. No driving restriction. Can take a second dose after 2 hours if needed.
• Nurtec ODT (Rimegepant): 75 mg orally disintegrating tablet. Approved for both acute treatment and prevention. Dissolves on tongue without water.
• Zavzpret (Zavegepant): 10 mg nasal spray. Fastest onset among the gepants. Good option if nausea makes oral medications difficult.

Triptans

• Sumatriptan: Generic, costs as little as $5–$20 for 9 tablets. Very effective but causes vasoconstriction — not safe for patients with cardiovascular disease.
• Other triptans include Rizatriptan, Zolmitriptan, and Eletriptan — all available as generics.

For a detailed comparison, read our full post on alternatives to Reyvow.

How to Find Reyvow in Stock While It Lasts

If you want to fill your existing Reyvow prescription before supply runs out:

1. Use Medfinder to search for pharmacies with current inventory
2. Try independent pharmacies — they may still have stock when chains run out
3. Fill early — don't wait until you're down to your last tablet
4. Ask your pharmacist if they can order Reyvow while wholesale distribution continues

For more strategies, check out how to find Reyvow in stock near you.

Final Thoughts

The Reyvow discontinuation is a loss for the migraine community. As the only medication in the ditan class, it offered something truly different — a non-vasoconstrictive acute treatment with a unique mechanism of action.

But the landscape of migraine treatment continues to evolve. Gepants offer many of the same advantages (no cardiovascular risk, no vasoconstriction) without the controlled substance classification or driving restrictions that held Reyvow back.

The most important thing you can do right now is talk to your doctor about a transition plan. Don't wait until Reyvow is completely unavailable to figure out your next medication. And in the meantime, Medfinder is here to help you find whatever supply remains.